Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.Findings published in the paper currently undergoing peer review and accessible on MEDRXIV, demonstrate Nu.Q® NETs H3.1 is a promising novel bioma ...